CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TOR1AIP2 (ImmuneEditome ID:163590)

1. Gene summary of enriched editing regions for TOR1AIP2

check button Gene summary
Gene informationGene symbol

TOR1AIP2

Gene ID

163590

GeneSynonymsIFRG15|LULL1|NET9
GeneCytomap

1q25.2

GeneTypeprotein-coding
GeneDescriptiontorsin-1A-interacting protein 2|interferon alpha responsive protein|15 kDa interferon-responsive protein|interferon responsive gene 15|lumenal domain like LAP1|torsin A interacting protein 2
GeneModificationdate20230517
UniprotIDQ8NFQ8;Q9H496;A0A096LNM1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:179842753-179843775:-ENST00000367612.6ENSG00000169905.11TOR1AIP2UTR3AluY,AluSz6,AluJrchr1:179842753-179843775:-.alignment
chr1:179859817-179860493:-ENST00000482587.4ENSG00000169905.11TOR1AIP2UTR3AluJr,AluJochr1:179859817-179860493:-.alignment
chr1:179862699-179863109:-ENST00000482587.4ENSG00000169905.11TOR1AIP2UTR3AluSx1,AluScchr1:179862699-179863109:-.alignment
chr1:179868904-179869262:-ENST00000474318.1ENSG00000169905.11TOR1AIP2ncRNA_exonicAluSpchr1:179868904-179869262:-.alignment
chr1:179873229-179875214:-ENST00000483123.1ENSG00000169905.11TOR1AIP2ncRNA_exonicAluSx1,MIR,MER5A,L1MC4a,FLAM_C,AluJr,AluJbchr1:179873229-179875214:-.alignment


Top

2. Tumor-specific enriched editing regions for TOR1AIP2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000169905.11,TOR1AIP2LUSCEAG4.0197e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr1:179859817-179860493:-ESCAPathEER3.5652e-025.3370e-030.2822image
ENSG00000169905.11,TOR1AIP2OVCliEAG2.9812e-023.9409e-030.1981image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr1:179859817-179860493:-HNSCEER5.2114e-033.3917e-021.2214e-01image

Top

3. Enriched editing regions and immune related genes for TOR1AIP2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for TOR1AIP2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000169905.11,TOR1AIP2
ESCAEAGESENSG00000078967.8chr743926517:43926556:43928013:43928111:43938430:43938494-0.34552.0889e-023.5617e-06-0.4026imageNADAR;BCCIP;CELF2;CNBP;CSTF2T;DDX3X;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RC3H1;SAFB2;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;TAF15;TARDBP;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMast_cells_restingGSVA_HALLMARK_MYC_TARGETS_V2

More results



Top

5. Enriched editing regions and immune infiltration for TOR1AIP2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:179859817-179860493:-BLCAEERMacrophages_M14.9083e-030.2174image
ENSG00000169905.11,TOR1AIP2BRCAEAGT_cells_gamma_delta1.7247e-020.0954image
chr1:179859817-179860493:-CHOLEERT_cells_regulatory_(Tregs)1.3838e-02-0.4857image
ENSG00000169905.11,TOR1AIP2CHOLEAGT_cells_regulatory_(Tregs)3.3507e-02-0.4029image
ENSG00000169905.11,TOR1AIP2COADEAGDendritic_cells_activated3.0762e-030.4860image
chr1:179859817-179860493:-ESCAEERMast_cells_resting3.6026e-02-0.2059image
chr1:179868904-179869262:-ESCAEERT_cells_CD4_naive4.9561e-030.3212image
chr1:179859817-179860493:-GBMEERB_cells_naive1.7934e-020.2577image
chr1:179859817-179860493:-HNSCEERB_cells_memory3.9153e-02-0.1548image
ENSG00000169905.11,TOR1AIP2HNSCEAGDendritic_cells_resting4.8838e-030.1815image
ENSG00000169905.11,TOR1AIP2KICHEAGT_cells_follicular_helper4.5836e-020.4402image
chr1:179859817-179860493:-KIRCEERMacrophages_M13.4904e-020.1952image
chr1:179859817-179860493:-KIRPEERT_cells_CD4_memory_activated2.7441e-020.2039image
ENSG00000169905.11,TOR1AIP2KIRPEAGT_cells_CD81.2352e-020.2214image
ENSG00000169905.11,TOR1AIP2LAMLEAGT_cells_regulatory_(Tregs)2.4961e-030.5488image
chr1:179859817-179860493:-LGGEERT_cells_CD4_naive9.5240e-03-0.2473image
ENSG00000169905.11,TOR1AIP2LGGEAGT_cells_CD4_naive1.5488e-02-0.1987image
chr1:179859817-179860493:-LIHCEERT_cells_follicular_helper4.4293e-03-0.1730image
ENSG00000169905.11,TOR1AIP2LIHCEAGT_cells_follicular_helper2.3541e-03-0.1779image
chr1:179859817-179860493:-LUADEERMacrophages_M19.7621e-030.1603image
ENSG00000169905.11,TOR1AIP2LUSCEAGPlasma_cells5.8853e-03-0.1784image
chr1:179859817-179860493:-MESOEERT_cells_CD4_memory_activated1.5126e-020.3149image
ENSG00000169905.11,TOR1AIP2MESOEAGT_cells_CD4_memory_activated4.4314e-030.3624image
chr1:179859817-179860493:-OVEERMonocytes2.0047e-020.1936image
chr1:179868904-179869262:-OVEERDendritic_cells_activated4.1257e-02-0.4196image
ENSG00000169905.11,TOR1AIP2OVEAGMonocytes9.8047e-040.2513image
chr1:179859817-179860493:-PCPGEEREosinophils9.8081e-050.4216image
ENSG00000169905.11,TOR1AIP2PCPGEAGEosinophils1.7189e-020.2310image
chr1:179859817-179860493:-PRADEEREosinophils8.1861e-040.4862image
ENSG00000169905.11,TOR1AIP2PRADEAGEosinophils3.3679e-050.4652image
chr1:179859817-179860493:-SKCMEERT_cells_follicular_helper2.0556e-020.1447image
chr1:179868904-179869262:-SKCMEERNeutrophils1.0579e-020.3550image
chr1:179859817-179860493:-STADEERMacrophages_M17.4323e-030.2149image
chr1:179873229-179875214:-STADEERT_cells_gamma_delta8.8147e-060.6984image
ENSG00000169905.11,TOR1AIP2STADEAGT_cells_follicular_helper3.5057e-020.1382image
chr1:179859817-179860493:-TGCTEERDendritic_cells_activated1.7336e-02-0.3743image
chr1:179859817-179860493:-THCAEERT_cells_regulatory_(Tregs)4.3419e-02-0.1322image
ENSG00000169905.11,TOR1AIP2THCAEAGT_cells_regulatory_(Tregs)1.0783e-02-0.1604image
ENSG00000169905.11,TOR1AIP2THYMEAGB_cells_memory2.1055e-02-0.3832image
chr1:179859817-179860493:-UCECEERDendritic_cells_activated2.8502e-020.3465image
ENSG00000169905.11,TOR1AIP2UCECEAGMacrophages_M01.5416e-02-0.2949image


Top

6. Enriched editing regions and immune gene sets for TOR1AIP2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000169905.11,TOR1AIP2ACCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG7.7792e-03-0.3918image
chr1:179859817-179860493:-ACCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.6878e-02-0.3585image
ENSG00000169905.11,TOR1AIP2BLCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG7.2379e-030.1782image
chr1:179859817-179860493:-BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.9171e-040.2533image
ENSG00000169905.11,TOR1AIP2BRCAGSVA_HALLMARK_MYC_TARGETS_V2EAG2.5614e-06-0.1871image
chr1:179859817-179860493:-BRCAGSVA_HALLMARK_HEME_METABOLISMEER1.0983e-040.1682image
ENSG00000169905.11,TOR1AIP2CESCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.6182e-020.1954image
chr1:179859817-179860493:-CESCGSVA_HALLMARK_NOTCH_SIGNALINGEER7.2335e-040.3310image
ENSG00000169905.11,TOR1AIP2COADGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.1768e-03-0.4723image
ENSG00000169905.11,TOR1AIP2ESCAGSVA_HALLMARK_MYC_TARGETS_V2EAG1.7439e-020.2036image
chr1:179868904-179869262:-ESCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER3.1856e-030.3362image
chr1:179859817-179860493:-ESCAGSVA_HALLMARK_MYC_TARGETS_V2EER4.7119e-020.1952image
chr1:179859817-179860493:-HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.2490e-020.1869image
ENSG00000169905.11,TOR1AIP2HNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG7.3939e-040.2168image
ENSG00000169905.11,TOR1AIP2KICHGSVA_HALLMARK_KRAS_SIGNALING_UPEAG4.0898e-03-0.5993image
ENSG00000169905.11,TOR1AIP2KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEAG6.5511e-030.2401image
chr1:179859817-179860493:-KIRPGSVA_HALLMARK_COMPLEMENTEER8.8836e-030.2409image
ENSG00000169905.11,TOR1AIP2LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.1671e-02-0.4697image
ENSG00000169905.11,TOR1AIP2LGGGSVA_HALLMARK_E2F_TARGETSEAG2.7311e-020.1814image
ENSG00000169905.11,TOR1AIP2LIHCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.1918e-030.1677image
chr1:179859817-179860493:-LIHCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.6177e-030.1828image
chr1:179859817-179860493:-LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.2298e-030.1696image
ENSG00000169905.11,TOR1AIP2LUADGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.4215e-020.1308image
chr1:179859817-179860493:-LUSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER9.2005e-030.2053image
ENSG00000169905.11,TOR1AIP2LUSCGSVA_HALLMARK_ANGIOGENESISEAG4.5092e-030.1839image
chr1:179859817-179860493:-MESOGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER5.1502e-030.3596image
chr1:179859817-179860493:-OVGSVA_HALLMARK_PEROXISOMEEER4.4472e-030.2358image
ENSG00000169905.11,TOR1AIP2OVGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.3874e-02-0.1552image
chr1:179868904-179869262:-OVGSVA_HALLMARK_APICAL_JUNCTIONEER4.7843e-020.4079image
ENSG00000169905.11,TOR1AIP2PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG6.0861e-03-0.3294image
chr1:179859817-179860493:-PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER8.4242e-030.3924image
ENSG00000169905.11,TOR1AIP2PRADGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.2178e-030.3403image
ENSG00000169905.11,TOR1AIP2SARCGSVA_HALLMARK_NOTCH_SIGNALINGEAG5.1540e-030.3430image
chr1:179859817-179860493:-SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0341e-020.3341image
chr1:179859817-179860493:-SKCMGSVA_HALLMARK_SPERMATOGENESISEER5.3168e-040.2150image
ENSG00000169905.11,TOR1AIP2SKCMGSVA_HALLMARK_MYOGENESISEAG8.3706e-03-0.1517image
ENSG00000169905.11,TOR1AIP2STADGSVA_HALLMARK_MYOGENESISEAG3.5279e-02-0.1380image
chr1:179873229-179875214:-STADGSVA_HALLMARK_PEROXISOMEEER4.1377e-04-0.5870image
ENSG00000169905.11,TOR1AIP2TGCTGSVA_HALLMARK_MYC_TARGETS_V1EAG1.2195e-03-0.3897image
chr1:179859817-179860493:-TGCTGSVA_HALLMARK_KRAS_SIGNALING_UPEER1.9667e-030.4747image
ENSG00000169905.11,TOR1AIP2THCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.4188e-03-0.1903image
chr1:179859817-179860493:-THCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER5.2868e-03-0.1818image
ENSG00000169905.11,TOR1AIP2THYMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG7.8075e-030.4363image
chr1:179859817-179860493:-UCECGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.6347e-020.3774image
ENSG00000169905.11,TOR1AIP2UCECGSVA_HALLMARK_MYC_TARGETS_V2EAG6.3719e-03-0.3301image
chr1:179859817-179860493:-UCSGSVA_HALLMARK_MYOGENESISEER1.4477e-020.5377image
ENSG00000169905.11,TOR1AIP2UCSGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.8493e-020.3652image


Top

7. Enriched editing regions and drugs for TOR1AIP2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000169905.11,TOR1AIP2ACCAZD6482EAG2.4270e-02-0.3355image
chr1:179859817-179860493:-ACCAZD6244EER5.6094e-030.4108image
chr1:179859817-179860493:-BLCAKIN001.135EER8.8811e-05-0.2994image
ENSG00000169905.11,TOR1AIP2BLCAImatinibEAG4.6911e-03-0.1874image
ENSG00000169905.11,TOR1AIP2BRCACCT007093EAG4.3315e-07-0.2008image
chr1:179859817-179860493:-BRCABosutinibEER3.8526e-050.1790image
ENSG00000169905.11,TOR1AIP2CESCAP.24534EAG1.2284e-02-0.2033image
chr1:179859817-179860493:-CESCAZD6482EER1.9604e-02-0.2319image
ENSG00000169905.11,TOR1AIP2CHOLCamptothecinEAG5.8677e-040.6088image
chr1:179859817-179860493:-CHOLCamptothecinEER1.0394e-020.5029image
ENSG00000169905.11,TOR1AIP2COADABT.888EAG2.3990e-02-0.3809image
chr1:179868904-179869262:-ESCAKIN001.135EER1.9066e-03-0.3528image
chr1:179859817-179860493:-ESCAFH535EER4.6182e-020.1960image
chr1:179859817-179860493:-GBMAMG.706EER8.0867e-030.2872image
ENSG00000169905.11,TOR1AIP2GBMFTI.277EAG3.2580e-020.2268image
ENSG00000169905.11,TOR1AIP2HNSCBosutinibEAG7.1587e-06-0.2858image
chr1:179859817-179860493:-HNSCAMG.706EER8.9846e-030.1953image
ENSG00000169905.11,TOR1AIP2KICHBryostatin.1EAG1.3383e-02-0.5304image
ENSG00000169905.11,TOR1AIP2KIRCAZD6244EAG3.7445e-020.1736image
ENSG00000169905.11,TOR1AIP2KIRPABT.263EAG1.6656e-02-0.2121image
chr1:179859817-179860493:-KIRPDMOGEER9.8025e-03-0.2379image
ENSG00000169905.11,TOR1AIP2LAMLA.770041EAG1.9688e-04-0.6473image
ENSG00000169905.11,TOR1AIP2LGGDocetaxelEAG4.0432e-02-0.1687image
ENSG00000169905.11,TOR1AIP2LIHCBryostatin.1EAG1.6875e-02-0.1402image
chr1:179859817-179860493:-LIHCAG.014699EER1.0132e-030.2031image
ENSG00000169905.11,TOR1AIP2LUADGemcitabineEAG7.4278e-040.1947image
ENSG00000169905.11,TOR1AIP2LUSCBIRB.0796EAG6.9455e-030.1749image
ENSG00000169905.11,TOR1AIP2MESOBMS.754807EAG4.8304e-020.2560image
chr1:179859817-179860493:-MESOAxitinibEER2.3555e-030.3886image
chr1:179868904-179869262:-OVGW843682XEER3.0510e-030.5787image
chr1:179859817-179860493:-OVAP.24534EER6.1371e-030.2274image
ENSG00000169905.11,TOR1AIP2OVBMS.536924EAG6.4850e-030.2086image
ENSG00000169905.11,TOR1AIP2PAADErlotinibEAG6.0500e-03-0.3370image
chr1:179859817-179860493:-PCPGBIRB.0796EER4.2719e-020.2272image
ENSG00000169905.11,TOR1AIP2PCPGCCT018159EAG9.9517e-03-0.2493image
chr1:179859817-179860493:-PRADGSK.650394EER3.0110e-030.4371image
ENSG00000169905.11,TOR1AIP2PRADLenalidomideEAG2.5860e-030.3476image
ENSG00000169905.11,TOR1AIP2SARCBMS.754807EAG2.2626e-03-0.3722image
chr1:179868904-179869262:-SKCMJNJ.26854165EER3.2561e-030.4043image
chr1:179859817-179860493:-SKCMBI.D1870EER3.0776e-03-0.1843image
ENSG00000169905.11,TOR1AIP2SKCMAG.014699EAG3.2196e-04-0.2060image
chr1:179859817-179860493:-STADDocetaxelEER2.3920e-02-0.1819image
chr1:179873229-179875214:-STADAZD.2281EER1.7253e-03-0.5320image
ENSG00000169905.11,TOR1AIP2STADJNJ.26854165EAG7.5197e-040.2193image
chr1:179859817-179860493:-TGCTBicalutamideEER2.2356e-03-0.4696image
ENSG00000169905.11,TOR1AIP2TGCTGemcitabineEAG1.3046e-040.4537image
ENSG00000169905.11,TOR1AIP2THCACEP.701EAG5.6591e-030.1738image
chr1:179859817-179860493:-THCABAY.61.3606EER4.7335e-03-0.1841image
ENSG00000169905.11,TOR1AIP2THYMAMG.706EAG1.8401e-03-0.5014image
chr1:179859817-179860493:-UCECBMS.509744EER1.1046e-020.3977image
ENSG00000169905.11,TOR1AIP2UCECEpothilone.BEAG7.5008e-030.3239image
ENSG00000169905.11,TOR1AIP2UCSAS601245EAG1.1752e-030.5192image
chr1:179859817-179860493:-UCSGSK.650394EER2.4404e-030.6386image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType